Navigation Links
Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
Date:11/9/2010

a.

GAAP operating expenses were $9.3 million and $34.0 million in the three and nine months ended September 30, 2010, respectively, compared to operating expenses of $13.0 million and $46.2 million in the same periods in 2009, respectively.  Research and development expenses were $6.7 million and $22.5 million in the three and nine months ended September 30, 2010, respectively, compared to $9.2 million and $32.2 million in the same periods in 2009, respectively.  The decrease in research and development expenses for the periods was primarily due to Alexza's restructuring announced in January 2009, at which time the Company reduced headcount by approximately 33% and focused its resources on the activities to support the AZ-004 NDA filing.  The 2010 results were also impacted by the reversal of accrued compensation and share-based compensation related to the 2010 bonus plan.  These bonus amounts were originally accrued assuming approval of the NDA for AZ-004 during 2010, and such amounts are no longer considered probable for payout in 2010.

General and administrative expenses were $2.6 million and $11.5 million in the three and nine months ended September 30, 2010, respectively, compared to $3.8 million and $11.9 million for the same periods in 2009, respectively.  The 2010 amounts were also impacted by the reversal of accrued compensation and share-based compensation related to the 2010 bonus plan.  These bonus amounts were originally accrued assuming approval of the NDA for AZ-004 during 2010, and such amounts are no longer considered probable for payout in 2010.

In connection with the acquisition of Symphony Allegro, Inc. in August 2009, Alexza is obligated to pay the former Symphony Allegro shareholders certain percentages of cash payments that may be generated from collaboration transactions for AZ-002 (Staccato alprazolam), AZ-004 or AZ-104 (Staccato loxapine, low-dose).  The Company records
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Inc. (Nasdaq: ISIS ) today reported net income ... and six months ended June 30, 2015, respectively, compared ... million for the same periods in 2014. Isis, significantly ... than $90 million of revenue Isis earned in the ... to license  ISIS-FXI Rx .  Isis increased its cash ...
(Date:8/4/2015)... FLORHAM PARK, N.J. , Aug. 4, ... partnered with University of Massachusetts Medical School,s ... enhancements and support regarding clinical protocols and ... Workflow Platform. Specialty medication ... ArmadaOne and helps to ensure optimal patient ...
(Date:8/4/2015)... -- Delcath Systems, Inc. (NASDAQ: DCTH ), a specialty ... an emphasis on the treatment of primary and metastatic ... studies in Europe and the ... Delivery System (CHEMOSAT) will be presented at the upcoming ... be held in Marseille, France , ...
Breaking Medicine Technology:Isis Reports Financial Results And Highlights For Second Quarter 2015 2Isis Reports Financial Results And Highlights For Second Quarter 2015 3Isis Reports Financial Results And Highlights For Second Quarter 2015 4Isis Reports Financial Results And Highlights For Second Quarter 2015 5Isis Reports Financial Results And Highlights For Second Quarter 2015 6Isis Reports Financial Results And Highlights For Second Quarter 2015 7Isis Reports Financial Results And Highlights For Second Quarter 2015 8Isis Reports Financial Results And Highlights For Second Quarter 2015 9Isis Reports Financial Results And Highlights For Second Quarter 2015 10Isis Reports Financial Results And Highlights For Second Quarter 2015 11Isis Reports Financial Results And Highlights For Second Quarter 2015 12Isis Reports Financial Results And Highlights For Second Quarter 2015 13Isis Reports Financial Results And Highlights For Second Quarter 2015 14Isis Reports Financial Results And Highlights For Second Quarter 2015 15Isis Reports Financial Results And Highlights For Second Quarter 2015 16Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 2Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 4
... Jan. 17, 2012 SIPP International Industries Inc. ... food and beverage, hospitality and medical technology industries announced ... FVJ Holdings, a Japanese Consulting firm based in Osaka ... begin generating additional residual revenues within three months.  ...
... HealthCare today announced latest data on its investigational compound ... Co lo r ectal cancer treated with re ... t herapy) trial. The study met its primary ... by 29% (HR=0.77, p=0.0052, median OS: 6.4 months vs. 5.0 ...
Cached Medicine Technology:SIPP International Industries, Inc. to Acquire Controlling Interest in FVJ Holdings out of Osaka Japan 2Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 2Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 3Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 4Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 5
(Date:8/5/2015)... ... , ... Over 6,500 athletes from 177 nations recently descended upon the Los ... World Games 2015 (July 25 to August 2). , Officially opened by First Lady ... since the 1984 Olympics, and the Los Angeles Coliseum was once again filled up ...
(Date:8/5/2015)... ... 2015 , ... The President of Wisdom Natural Brands®, parent ... year’s 50 Most Influential Women in Arizona by AZ Business Magazine. This coveted ... to the well-being of consumers through Wisdom Natural Brands’ groundbreaking products put her ...
(Date:8/4/2015)... ... ... MONTICELLO, Fla. – After completing 2,400 hours in the Clinical Pastoral Education ... a clinician allowed Dr. Barbara Thomas-Reddick to gain the skills and the ... families, friends and staff, and she was able to witness after leaving the patients’ ...
(Date:8/4/2015)... ... August 05, 2015 , ... The ... a 2015-2016 inductee into its VIP Woman of the Year Circle. She is ... leading networking organization exclusively for professional women, boasting more than 700,000 members and ...
(Date:8/4/2015)... ... August 04, 2015 , ... How cool is it to ... you via geolocation? The new "Now" feature will soon allow you to do just ... to inspire each other using the now feature. , Users will soon get to ...
Breaking Medicine News(10 mins):Health News:CPMA Member Podiatrists Ensure Fit Feet at the Special Olympics World Games in Los Angeles 2Health News:CPMA Member Podiatrists Ensure Fit Feet at the Special Olympics World Games in Los Angeles 3Health News:Carol May Named One of the Most Influential Woman in Arizona 2Health News:Carol May Named One of the Most Influential Woman in Arizona 3Health News:Carol May Named One of the Most Influential Woman in Arizona 4Health News:New book shows how ‘The Presence of a Chaplain’ affects lives 2Health News:New book shows how ‘The Presence of a Chaplain’ affects lives 3Health News:NAPW Inducts Deborah Stevens, Executive Assistant to Chairman and CEO at Mirion Technologies, Inc., Into its VIP Woman of the Year Circle 2Health News:Ahhaa App Soon to Release the "Now" Feature 2
... a major contributor to worldwide mortality and is characterized by ... vessel wall. This restricts blood supply to the tissues and ... implantation of a stent can successfully be used for revascularization ... However, when a regrowth of cells occurs in the inner ...
... (HealthDay News) -- ,Food ads have a powerful influence on ... to a new study. It included 75 children aged ... between each cartoon. Half the children saw a commercial for ... for French fries. After watching the cartoons and commercials, ...
... N.C. -- Cam Patterson, MD, MBA, division chief of ... Hill School of Medicine has been named the recipient ... Folkman Award in Vascular Biology. The award recognizes ... (within fifteen years of their first faculty appointment). Patterson ...
... Reporter , WEDNESDAY, Oct. 5 (HealthDay News) -- A novel ... some patients to cast away the medicines meant to keep ... small new study from the Stanford University School of Medicine. ... while they can greatly improve quality of life for someone ...
... of the daughters of women who had been given DES, ... that exposure to the drug while in the womb (in ... risk of certain cancers and pre-cancerous conditions. The results of ... (NCI), part of the National Institutes of Health, and collaborators ...
... HealthDay Reporter , WEDNESDAY, Oct. 5 (HealthDay ... closely mimic autism in humans. Though this isn,t ... this study come closer to mirroring all of the ... senior study author Matthew Anderson, an assistant professor of ...
Cached Medicine News:Health News:Extending the effective lifetime of stents 2Health News:TV Ads Whet Kids' Appetite for Junk Food 2Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 2Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 3Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 4Health News:Women exposed to diethylstilbestrol in the womb face increased cancer risk 2Health News:Women exposed to diethylstilbestrol in the womb face increased cancer risk 3Health News:Scientists Engineer Mice That Have Autism 2Health News:Scientists Engineer Mice That Have Autism 3
This is an antigen-capture assay intended for the detection of histidine-rich protein ll (PfHRP-ll), which is released from Malaria-infected red blood cells....
Malaria P.f. Rapid Test Device...
The Malaria Combo Test is a rapid test for the qualitative detection of Plasmodium falciparum and / or Plasmodium vivax , Plasmodium ovale and Plasmodium malariae antigen in whole blood. This ...
Core Malaria Pv/Pf is a self performing, qualitative, sandwich immunoassay for the detection and differentiation of vivax malaria and falciparum malaria in whole blood samples....
Medicine Products: